TITLE

Sustained Delivery of IL-1Ra from PF127-Gel Reduces Hyperglycemia in Diabetic GK-Rats

AUTHOR(S)
Akash, Muhammad Sajid Hamid; Rehman, Kanwal; Sun, Hongying; Chen, Shuqing
PUB. DATE
February 2013
SOURCE
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Interleukin-1beta (IL-1β) is a major cause for induction of various inflammatory mechanisms that are decisively involved to provoke pathogenesis of type 2 diabetes mellitus (T2DM). Interleukin-1 receptor antagonist (IL-1Ra) a naturally occurring anti-inflammatory antagonist of IL-1β has been recently approved for treatment of T2DM but due to its short half-life, higher doses and frequent dosing intervals are required. Pluronic F-127 (PF127) has previously shown to prolong the release of various proteinous drugs and their serum half-lives. Subsequently, in our previous work, we developed a new dosage form of IL-1Ra using PF127 and investigated its in-vitro and in-vivo effects. Here in present work, we have extended this approach using diabetic Goto-kakizaki (GK) rats. We administered IL-1Ra loaded in PF127 gel subcutaneously for one month into GK rats. IL-1Ra loaded in PF127 gel exhibited a sustained and prolonged hypoglycemic effects on treated animals. Intraperitoneal glucose tolerance test (IPGTT) results showed that IL-1Ra loaded in PF127 gel increased glucose tolerance along with increased insulin sensitivity and β-cell’s secretory function in treated rats. Moreover, significant reduction in pro-insulin/insulin ratio, lipid profiles and interleukin 6 (IL-6) were also observed. Immunohistochemical analysis showed slight macrophages infiltration in pancreatic islets. Histochemical analysis revealed no PF127-induced alteration in the normal physiology of skin and kidney of treated animals. Hence, we concluded that IL-1Ra loaded in PF127 gel has potential to exhibit broad spectrum anti-inflammatory effects alleviating the symptoms of T2DM.
ACCESSION #
87624121

 

Related Articles

  • Evidence That Multiple Defects in Lipid Regulation Occur before Hyperglycemia during the Prodrome of Type-2 Diabetes. Anderson, Simon G.; Dunn, Warwick B.; Banerjee, Moulinath; Brown, Marie; Broadhurst, David I.; Goodacre, Royston; Cooper, Garth J. S.; Kell, Douglas B.; Cruickshank, J. Kennedy // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Background: Blood-vessel dysfunction arises before overt hyperglycemia in type-2 diabetes (T2DM). We hypothesised that a metabolomic approach might identify metabolites/pathways perturbed in this pre-hyperglycemic phase. To test this hypothesis and for specific metabolite hypothesis generation,...

  • The Effect of Insulin Glargine on Glycemic Control in Hospitalized Patients with Diabetes Receiving Enteral Nutrition. Korytkowski, Mary; Salata, Rose; Koerbel, Glory; Dinardo, Monica; Karslioglu, Esra; Idriss, Almoatazbellah; Selzer, Faith; Banks, Tracey; Toledo, Frederico G. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA150 

    The article focuses on a study on the effect of insulin glargine on glycemic control in hospitalized patients with diabetes receiving enteral nutrition. Inpatients were assigned to glargine insulin with sliding scale regular (SSR) or SSR alone with neutral protamine Hagedorn (NPH) for persistent...

  • Individualizing Target Goals and Treatment in Patients with Type 2 Diabetes. SHAUGHNESSY, ALLEN F. // American Family Physician;6/1/2015, Vol. 91 Issue 11, p788 

    No abstract available.

  • A Polysaccharide Virulence Factor from Aspergillus fumigatus Elicits Anti-inflammatory Effects through Induction of Interleukin-1 Receptor Antagonist. Gresnigt, Mark S.; Bozza, Silvia; Becker, Katharina L.; Joosten, Leo A. B.; Abdollahi-Roodsaz, Shahla; van der Berg, Wim B.; Dinarello, Charles A.; Netea, Mihai G.; Fontaine, Thierry; De Luca, Antonella; Moretti, Silvia; Romani, Luigina; Latge, Jean-Paul; van de Veerdonk, Frank L. // PLoS Pathogens;Mar2014, Vol. 10 Issue 3, p1 

    The galactosaminogalactan (GAG) is a cell wall component of Aspergillus fumigatus that has potent anti-inflammatory effects in mice. However, the mechanisms responsible for the anti-inflammatory property of GAG remain to be elucidated. In the present study we used in vitro PBMC stimulation...

  • Comment on: Raz et al. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections Froma Diabetes Care Editors' Expert Forum. GIUGLIANO, DARIO; ESPOSITO, KATHERINE // Diabetes Care;Nov2013, Vol. 36 Issue 11, pe192 

    A letter to the editor is presented in response to the article "Personalized management of hyperglycemia in type 2 diabetes: reflections from a "Diabetes Care" Editors' Expert Forum," by I. Raz and colleagues in the 2013 issue.

  • New drug for type 2 diabetes.  // Clinical Advisor;Oct2009, Vol. 12 Issue 10, p15 

    The article offers information on the type 2 diabetes drug Onglyza from Bristol-Myers Squibb and AstraZeneca. It states that the drug should be added to diet and exercise as monotherapy or combination therapy and that the drug is not indicated for children. It cautions that the drug is not for...

  • Emerging Incretin-Based Therapies for Type 2 Diabetes: Incretin Mimetics and DPP-4 Inhibitors. Stonhouse, Anthony; Okerson, Ted; Kendall, David; Maggs, David // Current Diabetes Reviews;2008, Vol. 4 Issue 2, p101 

    Type 2 diabetes is a chronic disease characterized by impaired insulin action, progressive β-cell dysfunction as well as abnormalities in pancreatic α-cell function and postprandial substrate delivery. These pathophysiologic defects result in both persistent and progressive hyperglycemia,...

  • Prevalence of Hyper- and Hypoglycemia Among Inpatients With Diabetes. Wexler, Deborah J.; Meigs, James B.; Cagliero, Enrico; Nathan, David M.; Grant, Richard W. // Diabetes Care;Feb2007, Vol. 30 Issue 2, p367 

    The article presents a study on the prevalence of hyper- and hypoglycemia among inpatients with diabetes in the U.S. Data used in the study were derived from the University Health System Consortium (UHC) Diabetes Benchmarking Project and VHA Inc. It found that outpatient regimen disruptions and...

  • Majority of patients receive inadequate diabetes education.  // PharmacoEconomics & Outcomes News;6/14/2008, Issue 555, p9 

    The article presents the results of a survey by Roche Diagnostics which demonstrated that 94 percent of patients with type 2 diabetes mellitus are being failed because of inadequate diabetes education. It was found that one in three patients had not received any formation education courses in...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics